Ensysce Biosciences, Inc. Operating Income Loss

• Ensysce Biosciences, Inc. showed a decrease of -52.2% in Operating Income Loss from 2024 to 2025.
• This data is from Ensysce Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Ensysce Biosciences, Inc.'s Operating Income Loss has declined by 967.6%.
• Historical annual values: Fiscal year 2025: -$10.24 million | Fiscal year 2024: -$6.73 million | Fiscal year 2023: -$10.72 million | Fiscal year 2022: -$24.22 million | Fiscal year 2021: -$19.87 million | Fiscal year 2020: -$1.61 million | Fiscal year 2019: -$3.33 million | Fiscal year 2018: -$959.2 thousand.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026